Answer to Question 1
Correct Answer: 2
Rationale 1: Ritonavir is not the preferred drug to be used in combination with zidovudine for perinatal transmission prevention.
Rationale 2: The preferred drug to be used in combination with zidovudine for perinatal transmission prevention is lamivudine.
Rationale 3: Tenofovir is not the preferred drug to be used in combination with zidovudine for perinatal transmission prevention.
Rationale 4: Didanosine is not the preferred drug to be used in combination with zidovudine for perinatal transmission prevention.
Global Rationale: Recommended protocols for the pregnant woman include two NRTIs (zidovudine and lamivudine) with either an NNRTI (nevirapine) or a PI (lopinavir boosted with ritonavir). The specific regimen is adjusted based on resistance testing.
Answer to Question 2
Correct Answer: 2
Rationale 1: PEP should be started much sooner than 2 weeks after exposure.
Rationale 2: PEP should be started 2436 hours after exposure to be most successful.
Rationale 3: PEP should be started sooner than 3648 hours after exposure.
Rationale 4: PEP should be started sooner than 1 week after exposure.
Global Rationale: For prevention to be most successful, PEP should be started within 24 to 36 hours after exposure to a source person who is known to be HIV positive.
Subcutaneous drug administration: (a) cross section of skin showing depth of needle insertion;
) Subcutaneous drug administration: (b) the administration site is prepped
Subcutaneous drug administration: (d) the needle is removed and the puncture site is covered with an
Effect of pH on drug absorption: (a) a weak acid such as aspirin (ASA) is in a nonionized form in an
drug effects at synapses
Organizing Drug Information by Pharmacologic Classification